Abstract
Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression.
Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.Keywords: Autoantibodies, type 1 diabetes, prediction, prevention, biomarker, diabetogenesis.
Current Diabetes Reviews
Title:Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Volume: 13 Issue: 3
Author(s): Georgia Fousteri*, Elio Ippolito, Rizwan Ahmed and Abdel Rahim A. Hamad
Affiliation:
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan,Italy
Keywords: Autoantibodies, type 1 diabetes, prediction, prevention, biomarker, diabetogenesis.
Abstract: Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression.
Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.Export Options
About this article
Cite this article as:
Fousteri Georgia*, Ippolito Elio, Ahmed Rizwan and A. Hamad Rahim Abdel, Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666160427104157
DOI https://dx.doi.org/10.2174/1573399812666160427104157 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with an increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to microcirculatory disturbances and reduced levels of endogenous growth factors. Delayed cutaneous wound healing is a chronic ...read more
Advancing Insights into Type 1 Diabetes: From Mechanisms to Management
Type 1 diabetes (T1D) represents a significant global health challenge, requiring a deep understanding of its complex pathophysiology and the development of innovative strategies for prevention, treatment, and management. This thematic issue highlights the latest progress in understanding the autoimmune processes underlying T1D, advances in beta-cell biology, and novel therapeutic ...read more
Exerscience: management of diabetes by physical activity/exercise
Physical activity/exercise is key to the management of diabetes and its complications. Studies have suggested that increased physical activity or regular exercise is associated with reduced risks of diabetes and its complications. However, challenges remained on how to promote physical activity or exercise efficiently, e.g., increase the adherence to physical ...read more
Next-Generation Drug Delivery Systems for Diabetes: Nanoparticles, Hydrogels, and Phytosome Technologies
This thematic issue, titled "Next-Generation Drug Delivery Systems for Diabetes: Nanoparticles, Hydrogels, and Phytosome Technologies," will focus on advanced formulation science to enhance diabetes treatment. It covers innovative platforms such as nanoparticles, responsive hydrogels, and phytosome technologies for improving the bioavailability, stability, and precision in delivering antidiabetic agents. Key areas ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Lipid Disorders in Diabetes Mellitus and Current Management
Current Pharmaceutical Analysis Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature
Current Diabetes Reviews Discharge Planning for People with Inpatient Hyperglycaemia: A Review on Pharmacological Management
Current Diabetes Reviews Diabetes in Ethnically Diverse Youth: Disparate Burden and Intervention Approaches
Current Diabetes Reviews Neonatal Diabetes: Applying Molecular Biology to Patient Care
Current Pediatric Reviews Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Medicinal Plants for Diabetes Treatment During Pregnancy
Current Medicinal Chemistry Current Concepts in Gastric Motility in Diabetes Mellitus
Current Diabetes Reviews Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis
Current Diabetes Reviews Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets To Explore the Putative Molecular Targets of Diabetic Nephropathy and their Inhibition Utilizing Potential Phytocompounds
Current Medicinal Chemistry Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews